BCAX
Bicara Therapeutics Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$23.17
−0.73%Aug 11, 2026, 15:58 UTC
Bicara Therapeutics initiated the FORTIFI-FLEX trial, a pivotal Phase III study, and outlined an interim analysis timeline for mid-2027.
Source:Aug 11, 2026, 14:06 UTC
Bicara Therapeutics announced leadership changes during its Q2 2026 earnings call.
Jul 28, 2026, 00:00 UTC
Jeremy Bender was appointed as a Class I Director of the Board of Directors and a member of the Audit Committee and Launch Readiness Committee of Bicara Therapeutics Inc., effective July 28, 2026.
Jul 28, 2026, 00:00 UTC
Kiran Mazumdar-Shaw retired from the Board of Directors and the Nominating and Corporate Governance Committee of Bicara Therapeutics Inc., effective July 28, 2026.